Table of Contents
Molecular Biology International
Volume 2012 (2012), Article ID 643856, 4 pages
http://dx.doi.org/10.1155/2012/643856
Research Article

Relative Copy Number Variations of CYP2C19 in South Indian Population

1Pharmacogenomics Laboratory, Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India
2Onco-Hematology Unit, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland
3U 763, INSERM, Hopital Robert Debre, Paris, France

Received 29 March 2012; Accepted 28 April 2012

Academic Editor: George A. Calin

Copyright © 2012 Anichavezhi Devendran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Goldstein, “Clinical relevance of genetic polymorphisms in the human CYP2C subfamily,” British Journal of Clinical Pharmacology, vol. 52, no. 4, pp. 349–355, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Ingelman-Sundberg, S. C. Sim, A. Gomez, and C. Rodriguez-Antona, “Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects,” Pharmacology and Therapeutics, vol. 116, no. 3, pp. 496–526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Bertilsson, M. L. Dahl, M. Ingelman-Sundberg, I. Johansson, and F. Sjöqvist, “Interindividual and interethnic differences in polymorphic drug oxidation-implications for drug therapy with focus on psychoactive drugs,” in Advances in Drug Metabolism in Man, G. M. Pacific and G. N. Fracchia, Eds., pp. 85–136, Office for Official Publications of the European Communities, Luxembourg, 1995. View at Google Scholar
  4. K. Brøsen, S. M. F. de Morais, U. A. Meyer, and J. A. Goldstein, “A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype,” Pharmacogenetics, vol. 5, no. 5, pp. 312–317, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. K. J. Ellis, G. A. Stouffer, H. L. McLeod, and C. R. Lee, “Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations,” Pharmacogenomics, vol. 10, no. 11, pp. 1799–1817, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Murayama, N. Imai, T. Nakane, M. Shimizu, and H. Yamazaki, “Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes,” Biochemical Pharmacology, vol. 73, no. 12, pp. 2020–2026, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. N. He, F. X. Yan, S. L. Huang et al., “CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population,” European Journal of Clinical Pharmacology, vol. 58, no. 1, pp. 15–18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Desta, X. Zhao, J. G. Shin, and D. A. Flockhart, “Clinical significance of the cytochrome P450 2C19 genetic polymorphism,” Clinical Pharmacokinetics, vol. 41, no. 12, pp. 913–958, 2002. View at Google Scholar · View at Scopus
  9. M. Chang, M. L. Dahl, G. Tybring, E. Götharson, and L. Bertilsson, “Use of omeprazole as a probe drug for CYP2C19 phenotype in swedish caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype,” Pharmacogenetics, vol. 5, no. 6, pp. 358–363, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Hoskins, G. M. Shenfield, and A. S. Gross, “Concordance between proguanil phenotype and CYP2C19 genotype in Chinese,” European Journal of Clinical Pharmacology, vol. 59, no. 8-9, pp. 611–614, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Chang, G. Tybring, M. L. Dahl et al., “Interphenotype differences in disposition and effect on gastrin levels of omeprazole suitability of omeprazole as a probe for CYP2C19,” British Journal of Clinical Pharmacology, vol. 39, no. 5, pp. 511–518, 1995. View at Google Scholar · View at Scopus
  12. S. C. Sim, C. Risinger, M. L. Dahl et al., “A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants,” Clinical Pharmacology and Therapeutics, vol. 79, no. 1, pp. 103–113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Blaisdell, H. Mohrenweiser, J. Jackson et al., “Identification and functional characterization of new potentially defective alleles of human CYP2C19,” Pharmacogenetics, vol. 12, no. 9, pp. 703–711, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Arefayene, T. C. Skaar, X. Zhao et al., “Sequence diversity and functional characterization of the 5′-regulatory region of human CYP2C19,” Pharmacogenetics, vol. 13, no. 4, pp. 199–206, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Hanioka, Y. Tsuneto, Y. Saito et al., “Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population,” Xenobiotica, vol. 37, no. 4, pp. 342–355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Furuta, N. Shirai, M. Sugimoto, A. Nakamura, A. Hishida, and T. Ishizaki, “Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies,” Drug Metabolism and Pharmacokinetics, vol. 20, no. 3, pp. 153–167, 2005. View at Google Scholar · View at Scopus
  17. D. Taubert, H. J. Bouman, and J. W. Van Werkum, “Cytochrome P-450 polymorphisms and response to clopidogrel,” The New England Journal of Medicine, vol. 360, no. 21, pp. 2249–2250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. N. B. Norgard, K. D. Mathews, and G. C. Wall, “Drug-drug interaction between clopidogrel and the proton pump inhibitors,” Annals of Pharmacotherapy, vol. 43, no. 7-8, pp. 1266–1274, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Kim, J. S. Bertino Jr., A. Gaedigk, Y. Zhang, E. M. Sellers, and A. N. Nafziger, “Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker,” Clinical Pharmacology and Therapeutics, vol. 72, no. 2, pp. 192–199, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Rosemary, C. Adithan, N. Padmaja, C. H. Shashindran, N. Gerard, and R. Krishnamoorthy, “The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians,” European Journal of Clinical Pharmacology, vol. 61, no. 1, pp. 19–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Pastinen and T. J. Hudson, “Cis-acting regulatory variation in the human genome,” Science, vol. 306, no. 5696, pp. 647–650, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Fukushima-Uesaka, Y. Saito, K. Maekawa et al., “Genetic variations and haplotypes of CYP2C19 in a Japanese population,” Drug Metabolism and Pharmacokinetics, vol. 20, no. 4, pp. 300–307, 2005. View at Google Scholar · View at Scopus
  23. C. R.. Satyanarayana, A. Devendran, M. Jayaraman et al., “Influence of the genetic polymorphisms in the 5′ flanking and exonic regions of CYP2C19 on proguanil oxidation,” Drug Metabolism and Pharmacokinetics, vol. 24, no. 6, pp. 537–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. C. R. U. Satyanarayana, A. Devendran, R. Sundaram, S. D. Gopal, K. Rajagopal, and A. Chandrasekaran, “Genetic variations and haplotypes of the 5′ regulatory region of CYP2C19 in South Indian population,” Drug Metabolism and Pharmacokinetics, vol. 24, no. 2, pp. 185–193, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Hoebeeck, F. Speleman, and J. Vandesompele, “Real-time quantitative PCR as an alternative to southern blot or fluorescence in situ hybridization for detection of gene copy number changes,” Methods in Molecular Biology, vol. 353, pp. 205–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Löfgren, R. M. Baldwin, M. Hiratsuka et al., “Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression,” Drug Metabolism and Disposition, vol. 36, no. 5, pp. 955–962, 2008. View at Publisher · View at Google Scholar · View at Scopus